ArticleJournal of immunology (Baltimore, Md. : 1950)2010
Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells.
Article in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed.
- Beyond α-GalCer: Medicinal Chemistry Insights Driving Structural Evolution of CD1d Ligands.Journal of medicinal chemistry · 2026Review
- Synthetic Strategies and Immunological Evaluation of C-Linked α-Galactosylceramide Analogs.Advances in experimental medicine and biology · 2026Review
- Can invariant Natural Killer T cells drive B cell fate? a look at the humoral response.Frontiers in immunology · 2025Review
- State of play in the molecular presentation and recognition of anti-tumor lipid-based analogues.Frontiers in immunology · 2024Review
- CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy.Cancer cell international · 2023Review
- Harnessing invariant natural killer T cells to control pathological inflammation.Frontiers in immunology · 2022Review
- Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs.Animal diseases · 2022Article
- Transcriptome and chromatin landscape of iNKT cells are shaped by subset differentiation and antigen exposure.Nature communications · 2021Article
- A DesignedAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Modulation of Immune Responses to Influenza A Virus Vaccines by Natural Killer T Cells.Frontiers in immunology · 2020Review
- A molecular switch in mouse CD1d modulates natural killer T cell activation by α-galactosylsphingamides.The Journal of biological chemistry · 2019Article
- Development of α-GalCer Analogues with an α-Fluorocarbonyl Moiety as Th2-Selective Ligands of CD1d.ACS medicinal chemistry letters · 2019Article
- M2-specific reduction of CD1d switches NKT cell-mediated immune responses and triggers metaflammation in adipose tissue.Cellular & molecular immunology · 2018Article
- The Role of Natural Killer T Cells in Cancer-A Phenotypical and Functional Approach.Frontiers in immunology · 2018Review
- Harnessing Invariant NKT Cells to Improve Influenza Vaccines: A Pig Perspective.International journal of molecular sciences · 2017Review
- The hemochromatosis protein HFE 20 years later: An emerging role in antigen presentation and in the immune system.Immunity, inflammation and disease · 2017Review
- Natural Killer T Cells in Cancer Immunotherapy.Frontiers in immunology · 2017Review
- Carbohydrates as T-cell antigens with implications in health and disease.Glycobiology · 2016Review
- Glycolipid activators of invariant NKT cells as vaccine adjuvants.Immunogenetics · 2016Review
- The CD1 family: serving lipid antigens to T cells since the Mesozoic era.Immunogenetics · 2016Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Certain glycolipid Ags for Valpha14i NKT cells can direct the overall cytokine balance of the immune response. Th2-biasing OCH has a lower TCR avidity than the most potent agonist known, alpha-galactosylceramide. Although the CD1d-exposed portions of OCH and alpha-galactosylceramide are identical, structural analysis indicates that there are subtle CD1d conformational differences due to differences in the buried lipid portion of these two Ags, likely accounting for the difference in antigenic potency. Th1-biasing C-glycoside/CD1d has even weaker TCR interactions than OCH/CD1d. Despite this, C-glycoside caused a greater downstream activation of NK cells to produce IFN-gamma, accounting for its promotion of Th1 responses. We found that this difference correlated with the finding that C-glycoside/CD1d complexes survive much longer in vivo. Therefore, we suggest that the pharmacokinetic properties of glycolipids are a major determinant of cytokine skewing, suggesting a pathway for designing therapeutic glycolipids for modulating invariant NKT cell responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.